Article Sidebar

PDF
Date Published: 11/07/2022
Online Published: 11/07/2022
Abstract Views: 126
Views PDF: 115
DOI: https://doi.org/10.55046/vjrnm.28.474.2017
Issue
No. 28 (2017)
Section
Scientific research
How to Cite
Mai, H. S., & Le, N. H. (2022). 18Flourodeoxyglucose positron emission tomography/ computer tomography (18f-fdg pet/ct) for extranodal non hodgkin lym. Vietnamese Journal of Radiology and Nuclear Medicine, 28, 11-16. https://doi.org/10.55046/vjrnm.28.474.2017

18Flourodeoxyglucose positron emission tomography/ computer tomography (18f-fdg pet/ct) for extranodal non hodgkin lym

Mai Hong Son1, Le Ngoc Ha1,
1 Department of Nuclear Medicine, Central Military Hospital 108

Main Article Content

Abstract

SUMMARY


Background: the aim of our study to investigate the role of 18F-FDG PET/CT for extranodal lymphoma non Hodgkin in staging
and treatment response’s assessment. Methods: In our center, a total of 38 consecutive B-cell non- Hodgkin extranodal lymphoma patients were newly diagnosed between December 2013 to January 2016. All these patients were undergone 18F-FDG PET/CT scan before treatment, after 3- cycle and 6-cycle chemotherapy.
The assessment criteria were followed by modified Ann Aborr for staging and Lugano 2015 for treatment response.
Results: there were 13,2% of patients in stage IE, 7,9% in stage II3, 21,1% in stage IIIE and 47,9% ín stage IV. According to PET/CT staging, 56,2% of patients were upstaging in comparision to CT and 26,3% of patients have been changed in treatment’s stratergies. Kappa statistics revealed that CT and PET/CT showed fair agreement for the detection of extranodal lymphoma. After 6-cycle chemotherapy, 26/38 patients had no evidence of residuals or relapse and 7/38 patients showed partial response and 5/38 patients was in advanced diseases on PET/CT imaging. The positive and negative PET/CT after 3 cylces chemotherapy
may predicted the treatment’s response after 6 cylces (p=0.4).
Conclusions: 18F-FDG PET/CT has higher value than CT for staging and important role in assessment of treatment’s response
of extranodal lymphoma non Hodgkin patients.

Article Details

Keywords

non - Hodgkin lymphoma, Positron Emission Tomography/Computed Tomography, treatment response assessment

References

TÀI LIỆU THAM KHẢO
[1] Boellaard R. et al. (2010), “FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0”, Eur J Nucl Med Mol Imaging. 37 (1), pp. 181-200.
[2] Cronin C. G. et al. (2010), “Clinical utility of PET/CT in lymphoma”, AJR Am J Roentgenol. 194 (1), pp. W91-W103.
[3] Haioun C. et al. (2005), “[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive
lymphoma: an early prognostic tool for predicting patient outcome”, Blood. 106 (4), pp. 1376-1381.
[4] Wahl R. L. et al. (2009), “From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors”, J Nucl Med. 50 Suppl 1, pp. 122s-150s.
[5] Cheson B. D. (2015), “Staging and response assessment in lymphomas: the new Lugano classification”, Chin Clin Oncol. 4 (1), pp. 5.
[6] Omur O. et al. (2014), “Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and
Hodgkin lymphoma”, Diagn Interv Radiol. 20 (2), pp. 185-192.
[7] Pregno P. et al. (2012), “Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP”, Blood. 119 (9), pp. 2066-2073.
[8] Schaefer N. G. et al. (2004), “Non-Hodgkin Lymphoma and Hodgkin Disease: Coregistered FDG PET and CT
at Staging and Restaging—Do We Need Contrast-enhanced CT?”, Radiology. 232 (3), pp. 823-829.
[9] Society. A. C. (2009), “Cancer Facts & Figures”, 008. Available at: http://www.cancer.org/downloads/ STT/2008CAFFfinalsecured.pdf. Accessed March 11, 2009.